Diaceutics (LON:DXRX) Stock Price Up 0.7% – What’s Next?

Diaceutics PLC (LON:DXRXGet Free Report) shot up 0.7% during trading on Wednesday . The company traded as high as GBX 143 and last traded at GBX 143. Approximately 67,088 shares changed hands during trading, a decline of 68% from the average daily volume of 211,010 shares. The stock had previously closed at GBX 142.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group reissued a “buy” rating and set a GBX 215 price target on shares of Diaceutics in a research note on Wednesday, July 29th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of GBX 215.

Read Our Latest Stock Report on Diaceutics

Diaceutics Trading Up 0.7%

The firm’s 50-day simple moving average is GBX 141.76 and its 200-day simple moving average is GBX 152.09. The company has a quick ratio of 9.92, a current ratio of 3.43 and a debt-to-equity ratio of 2.85. The firm has a market capitalization of £121.02 million, a PE ratio of 1,300.00 and a beta of 0.89.

Diaceutics (LON:DXRXGet Free Report) last announced its quarterly earnings data on Tuesday, May 26th. The company reported GBX 11 earnings per share (EPS) for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%.The firm had revenue of GBX 3,844 million for the quarter. Equities analysts expect that Diaceutics PLC will post 1.0107919 earnings per share for the current year.

About Diaceutics

(Get Free Report)

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.

Featured Stories

Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.